ANUH PHARMA Latest Share Price (ANUHPHR)
TODAY IN ONE LINE
ANUHPHR surged 8.7% on above-average volume (2.1x avg), outperforming Nifty's -0.0% move, with no exchange filing today, suggesting a market-driven move.
With a market cap of ₹962.15 Cr., it trades at a P/E of 20.86. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
ANUH PHARMA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Promoter HoldingPromoters hold 71.8% skin-in-the-game
- ●Steady Dividend YieldReliable 1.66% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Promoter BuyingPromoters increased holdings by 71.77% QoQ
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 6.0% YoY
- ●Sales ContractionQuarterly sales dropped 74.9% YoY
- ●Rising Receivables vs SalesReceivables grew 17.1% outpacing sales growth of 2.2%
Latest ANUH PHARMA News
What changed recently?
Recent events, corporate actions, and announcements.
ANUH PHARMA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for ANUH PHARMA, framed against the sector median so the premium or discount is obvious at a glance.
ANUH PHARMA trades at a P/E of 20.86× and P/B of 2.62×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
ANUH PHARMA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for ANUH PHARMA — derived from the latest tape, not yesterday's close.
ANUH PHARMA last traded at ₹96.94 with an intraday range of ₹89.67–₹97.89 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹96.94| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 116.44 | +19.50 | +20.11% |
| R3 | 108.22 | +11.28 | +11.63% |
| R2 | 103.05 | +6.11 | +6.31% |
| R1 | 100.00 | +3.06 | +3.15% |
| PIVOT | 94.83 | -2.11 | -2.17% |
| CURRENT | 96.94 | — | — |
| S1 | 91.78 | -5.16 | -5.33% |
| S2 | 86.61 | -10.33 | -10.65% |
| S3 | 83.56 | -13.38 | -13.81% |
| S4 | 75.34 | -21.60 | -22.29% |
ANUHPHR is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹89.67–₹91.99
Trading Above opening range, showing Bullishness
ANUH PHARMA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for ANUH PHARMA — consolidated or standalone — with margins, YoY growth and key ratios inline.
ANUH PHARMA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹962.15 Cr. and reported EPS of ₹3.53.
ANUH PHARMA segment analysis : revenue and profit mix.
Disclosed business segments at ANUH PHARMA with their share of revenue and profit, switchable between consolidated and standalone reporting.
ANUH PHARMA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for ANUH PHARMA.
Our AI distills the core fundamental drivers supporting ANUH PHARMA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
ANUH PHARMA's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. Bedrock invocation timeout
Flip Conditions.
Valuation risk. a P/E above 27 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.83%.
ANUH PHARMA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — ANUH PHARMA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
ANUH PHARMA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for ANUH PHARMA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
ANUH PHARMA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for ANUH PHARMA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in ANUH PHARMA stood at 54.5% of traded volume, against a 20-day average of 57.5%.
ANUH PHARMA announcements: results, concalls, ratings, M&A.
Filings ANUH PHARMA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
ANUH PHARMA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 76 documents below.
Investor Presentation
Anuh Pharma Limited has informed the Exchange about Investor Presentation
Change in Management
Anuh Pharma Limited has informed the Exchange about change in Management
Appointment
Anuh Pharma Limited has informed the Exchange regarding Appointment of Mr Bipin N. Shah, Mr. Arun L. Todarwal and Mr. Ankit Chande as Directors of…
General Updates
Anuh Pharma Limited has informed the Exchange about General Updates under Regulation 30.
Shareholders meeting
Anuh Pharma Limited has submitted the Exchange a copy Voting Results and Scrutinizers report of Annual General Meeting held on August 12, 2026.
Investor decks & rating reports.
ANUH PHARMA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue ANUH PHARMA has declared, sequenced by announce and record date.
ANUH PHARMA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About ANUH PHARMA: business, sector, key facts.
What ANUH PHARMA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
ANUH PHARMA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: ANUHPHR, BSE: 506260.
Anuh Pharma Limited is an Indian pharmaceutical company primarily focused on the manufacturing and sale of bulk drugs and chemicals. Its core business revolves around the production of Active Pharmaceutical Ingredients (APIs), which are the fundamental components used in the formulation of various medicines. This makes Anuh Pharma a key player in the pharmaceutical supply chain, rather than directly selling finished medications to consumers.
The company's API portfolio is quite diverse, encompassing a wide range of therapeutic areas. Key product categories include macrolides (a class of antibiotics), anti-tuberculosis drugs, anti-malarial medications, and various antibacterial agents. Beyond infectious disease treatments, Anuh Pharma also produces APIs for cardiovascular health (anti-hypertension drugs) and respiratory conditions (expectorants). Further broadening their product line, they offer quinolones (another class of antibiotics) and essential intermediates used in the synthesis of other APIs. This demonstrates a strategic approach to supplying raw materials for a significant portion of the pharmaceutical market.
In addition to its extensive range of antibiotics and cardiovascular APIs, Anuh Pharma also manufactures corticosteroids. These versatile drugs have a variety of applications, including anti-inflammatory, immunosuppressant, anti-pruritic (anti-itch), anti-mitotic (cell division inhibiting), and anti-histamine properties. This further diversifies their product offering and caters to a broader range of pharmaceutical needs. The production of corticosteroids showcases Anuh Pharma's capability in complex chemical synthesis and manufacturing processes.
An important aspect of Anuh Pharma's business model is its export operations. The company actively engages in international trade, selling its APIs to pharmaceutical companies and manufacturers in various countries. This signifies a significant presence in the global pharmaceutical supply chain and contributes to the company's revenue generation. The international market access enhances its reach and potential for growth.
Established in 1960 and headquartered in Mumbai, Anuh Pharma has a long history of operation within the Indian pharmaceutical industry. Its longevity and consistent production of a broad array of APIs illustrate a commitment to quality and sustained relevance in a competitive market. The company’s continued success likely hinges on its ability to adapt to evolving market demands and technological advancements in pharmaceutical manufacturing.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B BLACKBIO DX (3BBLACKBIO) Share PricePeer
- ABBOTT INDIA (ABBOTINDIA) Share PricePeer
- ACUTAAS CHEMICALS (ACUTAAS) Share PricePeer
- ANLON HEALTHCARE (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Top Gainers TodayScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about ANUH PHARMA (ANUHPHR).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of ANUH PHARMA (ANUHPHR)?
The current share price of ANUH PHARMA (ANUHPHR) is ₹96.94. Today, the stock has gained by ₹7.72 (8.65%), trading in a range of ₹89.67 to ₹97.89. The stock opened at ₹89.67 with a trading volume of 1,95,701 shares.
02Is ANUH PHARMA stock a good investment for long-term?
ANUH PHARMA can be considered for long-term investment based on several factors. The company has a market capitalization of ₹962.15 Cr., P/E ratio of 20.86, ROE of 11.65%, and ROCE of 11.96%. The dividend yield stands at 1.66%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of ANUH PHARMA stock?
The 52-week high price of ANUH PHARMA (ANUHPHR) is ₹99.50, while the 52-week low is ₹67.00. Currently trading at ₹96.94, the stock is 44.69% above its 52-week low and 2.57% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy ANUH PHARMA stock at the current price?
Whether to buy ANUH PHARMA stock at ₹96.94 depends on multiple factors. The stock is currently trading with a P/E ratio of 20.86 and P/B ratio of 2.62. Today's performance shows a gain of 8.65%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of ANUH PHARMA and when is the next dividend?
ANUH PHARMA offers a dividend yield of 1.66%, which means for every ₹100 invested at the current price of ₹96.94, you can expect to receive approximately ₹1.66 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of ANUH PHARMA?
ANUH PHARMA's key financial metrics include: P/E Ratio: 20.86, P/B Ratio: 2.62, ROE: 11.65%, ROCE: 11.96%, Dividend Yield: 1.66%, EPS: ₹3.53, Book Value: ₹35.14, and Debt-to-Equity: 0. The company's market cap stands at ₹962.15 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is ANUH PHARMA stock performing today in the market?
ANUH PHARMA stock opened at ₹89.67 and is currently trading at ₹96.94, showing a gain of ₹7.72 (8.65%). The intraday high is ₹97.89 and low is ₹89.67. The trading volume stands at 1,95,701 shares, indicating moderate market participation today.
08What is the P/E ratio of ANUH PHARMA and what does it indicate?
ANUH PHARMA has a Price-to-Earnings (P/E) ratio of 20.86, which means investors are willing to pay 20.86 for every ₹1 of earnings. With an EPS of ₹3.53, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about ANUH PHARMA (ANUHPHR) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.